NASDAQ:VVUSVIVUS Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding VIVUS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.12 -0.05 (-4.27 %) (As of 06/1/2020 04:00 PM ET) Add Compare Share Today's Range$1.10Now: $1.12▼$1.1750-Day Range$1.05MA: $1.23▼$1.3952-Week Range$0.80Now: $1.12▼$4.75Volume382,900 shsAverage Volume593,830 shsMarket Capitalization$20.01 millionP/E RatioN/ADividend YieldN/ABeta-0.79 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media VIVUS, Inc. operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol. It also provides PANCREAZE to treat exocrine pancreatic insufficiency due to cystic fibrosis or other conditions; and STENDRA/SPEDRA, an oral phosphodiesterase type 5 inhibitor for erectile dysfunction. In addition, the company is developing Qsymia, which has completed Phase II clinical study for treating various diseases, including obstructive sleep apnea, diabetes, and nonalcoholic steatohepatitis; and VI-0106 that has completed Phase IIa study to treat patients with pulmonary arterial hypertension. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation; Menarini Group; Sanofi; Metuchen Pharmaceuticals, LLC; Selten Pharma, Inc.; Alvogen Malta Operations (ROW) Ltd; and Janssen Pharmaceuticals, Inc. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California.Read More Beat the Market (BTM) Rank™ 3.0 Analyst's Opinion Consensus RatingVIVUS has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.75, VIVUS has a potential upside of 56.3% from its current price of $1.12.Amount of Analyst CoverageVIVUS has only been the subject of 1 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesVIVUS has received 375 “outperform” votes. (Add your “outperform” vote.)Underperform VotesVIVUS has received 439 “underperform” votes. (Add your “underperform” vote.)Community SentimentVIVUS has received 53.93% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about VIVUS and other stocks. Vote “Outperform” if you believe VVUS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VVUS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldVIVUS does not currently pay a dividend.Dividend GrowthVIVUS does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, VIVUS insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 12.00% of the stock of VIVUS is held by insiders.Percentage Held by InstitutionsOnly 7.32% of the stock of VIVUS is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for VIVUS are expected to grow in the coming year, from ($2.27) to ($1.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of VIVUS is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VIVUS is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.19 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:VVUS Previous Symbol CUSIP92855110 CIK881524 Webwww.vivus.com Phone650-934-5200Debt Debt-to-Equity RatioN/A Current Ratio0.43 Quick Ratio0.28Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$69.76 million Price / Sales0.29 Cash FlowN/A Price / Cash FlowN/A Book Value($6.50) per share Price / Book-0.17Profitability EPS (Most Recent Fiscal Year)($2.96) Net Income$-31,500,000.00 Net Margins-39.28% Return on EquityN/A Return on Assets-12.18%Miscellaneous Employees57 Outstanding Shares17,870,000Market Cap$20.01 million Next Earnings Date8/4/2020 (Estimated) OptionableOptionable NASDAQ:VVUS Rates by TradingView Receive VVUS News and Ratings via Email Sign-up to receive the latest news and ratings for VVUS and its competitors with MarketBeat's FREE daily newsletter. VIVUS (NASDAQ:VVUS) Frequently Asked Questions How has VIVUS's stock been impacted by COVID-19 (Coronavirus)? VIVUS's stock was trading at $1.04 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, VVUS shares have increased by 7.7% and is now trading at $1.12. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of VIVUS? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VIVUS in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for VIVUS. When is VIVUS's next earnings date? VIVUS is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for VIVUS. How were VIVUS's earnings last quarter? VIVUS, Inc. (NASDAQ:VVUS) issued its earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.31. The biopharmaceutical company had revenue of $19.63 million for the quarter. View VIVUS's earnings history. When did VIVUS's stock split? How did VIVUS's stock split work? VIVUS shares reverse split before market open on Tuesday, September 11th 2018. The 1-10 reverse split was announced on Monday, September 10th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 10th 2018. An investor that had 100 shares of VIVUS stock prior to the reverse split would have 10 shares after the split. What price target have analysts set for VVUS? 1 brokerages have issued 12 month target prices for VIVUS's stock. Their forecasts range from $1.75 to $1.75. On average, they expect VIVUS's stock price to reach $1.75 in the next year. This suggests a possible upside of 56.3% from the stock's current price. View analysts' price targets for VIVUS. Has VIVUS been receiving favorable news coverage? News articles about VVUS stock have trended very positive recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. VIVUS earned a media sentiment score of 3.5 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutVIVUS. Who are some of VIVUS's key competitors? Some companies that are related to VIVUS include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT). View all competitors. What other stocks do shareholders of VIVUS own? Based on aggregate information from My MarketBeat watchlists, some companies that other VIVUS investors own include Novavax (NVAX), Sangamo Therapeutics (SGMO), Anavex Life Sciences (AVXL), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Advanced Micro Devices (AMD), Melinta Therapeutics (MLNT), Inovio Pharmaceuticals (INO), General Electric (GE) and Pfizer (PFE). Who are VIVUS's key executives? VIVUS's management team includes the following people: Mr. John P. Amos, CEO & Director (Age 52)Mr. Kenneth Suh, Pres (Age 43)Mr. Mark K. Oki, Sr. VP, CFO & Chief Accounting Officer (Age 50)Mr. John L. Slebir, Sr. VP of Bus. Devel., Gen. Counsel & Sec. (Age 54)Dr. Santosh T. Varghese, Chief Medical Officer (Age 49) What is VIVUS's stock symbol? VIVUS trades on the NASDAQ under the ticker symbol "VVUS." Who are VIVUS's major shareholders? VIVUS's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.22%). Company insiders that own VIVUS stock include Eric W Roberts, John P Amos and Mark K Oki. View institutional ownership trends for VIVUS. Which major investors are selling VIVUS stock? VVUS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc.. View insider buying and selling activity for VIVUS. How do I buy shares of VIVUS? Shares of VVUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is VIVUS's stock price today? One share of VVUS stock can currently be purchased for approximately $1.12. How big of a company is VIVUS? VIVUS has a market capitalization of $20.01 million and generates $69.76 million in revenue each year. The biopharmaceutical company earns $-31,500,000.00 in net income (profit) each year or ($2.96) on an earnings per share basis. VIVUS employs 57 workers across the globe. What is VIVUS's official website? The official website for VIVUS is www.vivus.com. How can I contact VIVUS? VIVUS's mailing address is 900 E. HAMILTON AVENUE SUITE 550, CAMPBELL CA, 95008. The biopharmaceutical company can be reached via phone at 650-934-5200 or via email at [email protected] This page was last updated on 6/2/2020 by MarketBeat.com Staff
